A large number of studies have shown that higher total cfDNA levels can be detected in the plasma of cancer patients, although, especially in late tumour stages 11. To date, it remains unclear how the lengths of nuclear and mitochondrial cfDNA fragments contribute to total cfDNA quantity and whether they can be used as sensitive and reliable biomarkers in CRC diagnostics. It is considered that tumour-derived necrotic DNA degradation results in cfDNA fragments with a length of > 250 bp, whereas normal apoptotic cells produces fragments of around 180 bp or less 15, 26. An increased ratio between long to small fragments (DII) was found in a significant number of studies but others did not support this theory 17, 18, 27, 28.
Our study was designed to specifically address the question whether short and/or long fragments were altered in CRC patients compared to healthy individuals. Therefore, we intended to precisely measure n-cfDNA and mt-cfDNA independent from total concentration of isolated cfDNA, arguing that the ratio between small and long fragments in cfDNA samples from certain study groups must remain identical.
In agreement with previous findings12, we detected a higher concentration of total cfDNA in plasma samples of CRC patients compared to healthy controls. In addition, the level was observed to increase with the pathological stage of CRC, suggesting an increase with tumour malignancy.
Using equal cfDNA concentration (ETC) as template for qPCR analysis, control and CRC patients showed similar levels of both KRAS 67 and Alu 115 markers. This outcome also remains unaltered in all stages of CRC, highlighting that there is no measurable difference in short n-cfDNA fragment levels between healthy and cancer group at ETC condition. However, regarding long fragments of both n-cfDNA markers KRAS 305 and Alu 247, a significant decrease was detected comparing both cohorts. Strikingly, decreased levels of long n-cfDNA fragments was also observed in later stages of CRC, although with a statistical significance only in stage IV, indicating that advanced tumour malignancy inversely contribute to n-cfDNA stability. Likewise, significantly reduced DII scores were detected for both KRAS 305/67 and Alu 247/115. Primarily, significant reductions were observed in UICC stage IV, with the most pronounced decrease of long n-cfDNA fragments. Importantly, the results changed profoundly when the qPCR data was normalized to the actual cfDNA concentration of each sample (NTC). We believe that this approach mostly resembles previous qPCR analysis, in which cfDNA samples were analysed via qPCR independent from its concentration. Accordingly, the level of short n-cfDNA fragments significantly increases in the CRC cohort and with higher pathological stages. This result demonstrates that the n-cfDNA concentration is generally higher in the plasma of CRC patients and confirmed previous findings 13, 14, 17–19, 27, 29. For long n-cfDNA fragments at NTC condition, the calculated quantities of both KRAS 305 as well as Alu 247 did not significantly differ between healthy individuals and all stages of CRC patients. Although, we noticed a slight increase in the level of both markers from stage II to IV, this observation was without statistical significance. At this point, our findings differed from previous studies, that reported elevated cfDNA levels including long fragmented markers 17, 18. Nevertheless, Mead et. al. reported increased median levels of total cfDNA and Alu 115 rising from control to benign polyps and cancer group, whereas long fragment levels of Alu (247) and Line1 (300) were comparable or even lower in CRC patients compared to individuals with benign polyps 17. Furthermore, the integrity index of patients with different histopathological stages of CRC were reported to significantly decrease in stage IV compared to stage II. This observation might be explained by an increase in the level of Alu 83 that was more profound compared to that of Alu 244 18.
We assume that, under NTC condition, the level of especially short n-cfDNA fragments in the plasma of CRC patients increases proportional to the level of total cfDNA, particularly in advanced stages of CRC. In contrast, long n-cfDNA fragments did not, suggesting that increased levels of total cfDNA in CRC patients is not associated with raised necrotic cellular degradation. This result is also in accordance with a recent view, whereby increased tumor-derived cfDNA quantity predominantly comprises shorter fragments compared to healthy individuals 27. In further support to our view, massive parallel sequencing of cfDNA extracted from plasma of hepatocellular carcinoma patients revealed significantly lower levels of long fragmented cfDNA 30.
The analysis of short and long fragments of MTCO3 revealed a highly significant decrease of both markers in CRC group at ETC condition. Moreover, both fragment levels were significantly reduced in almost all stages of CRC with the exception of stage III. Considering the relevance of especially early stages (I and II) for CRC detection, our data suggests an improvement for cfDNA-based diagnostics using mitochondrial markers. Of note, decreased mt-cfDNA levels were also found when normalizing our data to the total cfDNA concentration (NTC). However, this approach remarkably reduced the difference in mt-cfDNA quantity between CRC and control group as well as UICC stages, relative to the data obtained from equal template concentration. Thus, our findings may have unravelled a weak point of using unequalized total cfDNA concentrations as template in qPCR-based CRC diagnostics (NTC) and provides additional evidence for the usefulness of our approach (ETC). Surprisingly, although weak, the DII of mt-cfDNA fragments in CRC patients was significantly higher compared to healthy individuals. This observation was in contrast to the DII of n-cfDNA and may be due to significant differences between healthy individuals and CRC patients in long and short MTCO3 fragment levels. At this point, our data further suggest a fundamental difference between n-cfDNA and mt-cfDNA with regard to its integrity. However, we can only speculate whether this difference is due to an alternate origin or mode of degradation. Of note, mitochondrial DNA lacks a nucleosomal core structure and it was recently published that plasmatic mt-cfDNA is more stable compared to n-cfDNA 31. In addition, it was reported that a substantial amount of entire cell-free mitochondria with intact respiratory metabolism are present in human plasma, next to its known presents in microvesicles 31. Nonetheless, in our view, the prognostic value of mitochondrial DII is questionable at this point, since there is no significant difference between the UICC stages. Even so, we confirmed previous findings, in which mt-cfDNA concentration in CRC patients decreases significantly compared to healthy individuals 19.
Generally, we believed that the contribution of tumour-specific n- and mt-cfDNA might be far too low to explain the elevated total cfDNA level or changes in the DII in plasma of CRC patients. It is therefore necessary to consider other non-malignant cells or cellular processes as a major source of cfDNA. This is supported by research that has shown that stromal, endothelial and immune cells also constitute to the microenvironment of tumour tissue either to support or to oppose cancer formation 32. Therefore, although it is plausible that senescent tumour cells in CRC patients are frequently undergoing necrosis, cancer cell death might be covered by enhanced apoptosis from yet unknown cell origin.
An additional important objective of this study was to determine marker-specific cutoffs for the diagnostic use of biomarkers to differentiate groups. Specifically, we report the cut-offs for the following group differentiations: 1) healthy control versus total CRC patients, 2) healthy control versus CRC patients with UICC stage I and II, group 3) healthy control versus patients with stage III and IV, and group 4) UICC stage I and II versus stage III and IV. Therefore, we either used the data measured unrelated to (ETC) or dependent on the total cfDNA concentration (NTC) (Table S3). Of note, total cfDNA concentration measured spectrophotometrically yielded one of the highest AUCs in all four group differentiations and indicates the best CRC detection rate for patients with later stadium III/IV. With regard to previous studies, in which a comparable detection method was used, our results performed moderately better. For early stages (I/II), an AUC of 0.64 (P = 0.03) with 42% sensitivity and 75% specificity and for later stages (III/IV) an AUC of 0.63 (P = 0.003) with 63% sensitivity and 75% specificity was reported 33. El-Gayar et al. distinguished CRC patients from healthy donors with an AUC of 73% (P = 0.004), a sensitivity of 68% and a specificity of 65% 14.
For the evaluation of diagnostic potential using single markers, best results were obtained for both mt-cfDNA fragments in the ETC condition, thus highlighting the potential of mt-cfDNA biomarkers in early stage CRC detection. This result is in agreement with data from Mead et al., in which ROC curve analysis of a single mt-cfDNA marker were able to significantly (P < 0.001) differentiate patients (polyps and CRC) from healthy control 17. For single nt-cfDNA marker quantities, highest diagnostic accuracies were obtained for longer fragments of KRAS and Alu in the ETC condition and shorter fragments KRAS and Alu in the NTC condition. However, detection of CRC with high sensitivity and specificity was only reached in advanced tumour progression (UICC stages III and IV), suggesting a subordinate importance of these markers for early diagnosis.
In our study, the DII of nt-cfDNA and mt-cfDNA proved to be effective determinants to significantly differentiate the aforementioned groups. However, we conclude that DII scores from both n- and mt-cfDNA markers in our analysis did not performed superior compared to single markers, and especially with regard to the total cfDNA concentration. In our view, this could be explained by the fact that DII determination as the ratio between long and short fragment quantities is limited by the discriminatory capability of either of its “best” single marker. For example, at ETC condition, the median quantity of Alu 247 fragments performed best, whereas in the NTC condition Alu 115 seemed to be a more reliable marker (Figs. 1 and 2).
Using LASSO multinomial logistic regression, a modern and robust statistical technique that circumvents multicollinearity problems between predictor variables that is able to identify important predictors and provide robust estimates, we investigated the relationship between biomarkers and UICC stages of colorectal cancer. We applied this modelling approach to different sets of predictor variables and evaluated the predictive accuracy of the different models using misclassification error. Both models based on a single set of biomarkers (ETC or NTC) resulted in approximately equal diagnostic prediction accuracy, whereas the model that included biomarkers of the ETC and NTC condition had approximately 30% lower misclassification error rates. Interestingly, only long fragmented biomarkers were selected as predictors in the final model, with the exception of the MTCO3 marker (67bp).